Panic Disorder Market Report and Forecast 2025-2034
Description
The panic disorder market size in the 7 major markets was valued at USD 9.70 Billion in 2024, driven by the increased emphasis on improving mental health. The market is expected to grow at a CAGR of 4.18% during the forecast period of 2025-2034, with the values likely to reach USD 14.61 Billion by 2034.
Panic Disorder: Introduction
Panic disorder is characterized by a condition with recurring and frequent panic attacks. They are repeated episodes of intense anxiety and fear, accompanied by physical symptoms like nausea, trembling, sweating and palpitations. Symptoms can also be triggered using amphetamines, cocaine, marijuana, hallucinogens, alcohol, and other drugs. Panic disorders are frequently treated through antidepressants, benzodiazepines, cognitive as well as behavioral therapies.
Panic Disorder Market Analysis
Pharmacological intervention is one of the most common panic disorder treatments. Over the years, there has been development of several medications like diazepam, alprazolam, clonazepam, paroxetine, venlafaxine, clomipramine, fluoxetine and adinazolam, helping many patients cope with the symptoms. Owing to the high panic disorder market demand, the FDA has also approved several medications such as Cymbalta (duloxetine delayed-release capsules), Effexor XR (venlafaxin HCL) and Zoloft (sertraline HCl) among others.
Along with pharmaceuticals, CBT (cognitive behavioral therapy) has shown promising results for treating panic disorders. Panic-focused psychodynamic psychotherapy, eye movement desensitization and reprocessing (EMDR) therapy and applied relaxation training (ART) are frequently applied, depending on the symptoms of the patients. Meditation is also promoted as a treatment for relieving anxiety symptoms.
The increasing integration of digital and artificial intelligence enabled tools into the medical ecosystem has propelled the panic disorder market growth. Smartphone apps to help manage anxiety have emerged in the market. For instance, the Mindable app, developed by professors at Constructor University in Bremen has been approved to manage panic disorder and agoraphobia. Similarly, Apple has launched their ‘Rootd’, facilitating the consumers with panic conditions.
Panic Disorder Market Segmentation
“Panic Disorder Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The United States hold a significant panic disorder market share and is likely to continue dominating the market in the coming years as well. With prominent companies prevailing in the region, the frequency of drug development and approvals is high. There is rising awareness on mental health related issues with government and private foundations stepping in with campaigns and seminars to impart relevant knowledge on the issues.
In Europe, traditional techniques like aromatherapy and meditation are on the rise. The EU commission has announced a hefty investment of 6 million euros as a part of their mental health strategy. Moreover, workplace mental health initiatives have also been taken on the psychosocial risks of burnout in offices.
The Asia Pacific panic disorder market value is anticipated to grow with reducing stigmatization of mental health issues. With the help non-profit organizations and government campaigns, the masses are getting more aware about the condition. Moreover, the region is also experiencing improvements in the healthcare ecosystem to provide better treatment alternatives to the patients.
Panic Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Panic Disorder: Introduction
Panic disorder is characterized by a condition with recurring and frequent panic attacks. They are repeated episodes of intense anxiety and fear, accompanied by physical symptoms like nausea, trembling, sweating and palpitations. Symptoms can also be triggered using amphetamines, cocaine, marijuana, hallucinogens, alcohol, and other drugs. Panic disorders are frequently treated through antidepressants, benzodiazepines, cognitive as well as behavioral therapies.
Panic Disorder Market Analysis
Pharmacological intervention is one of the most common panic disorder treatments. Over the years, there has been development of several medications like diazepam, alprazolam, clonazepam, paroxetine, venlafaxine, clomipramine, fluoxetine and adinazolam, helping many patients cope with the symptoms. Owing to the high panic disorder market demand, the FDA has also approved several medications such as Cymbalta (duloxetine delayed-release capsules), Effexor XR (venlafaxin HCL) and Zoloft (sertraline HCl) among others.
Along with pharmaceuticals, CBT (cognitive behavioral therapy) has shown promising results for treating panic disorders. Panic-focused psychodynamic psychotherapy, eye movement desensitization and reprocessing (EMDR) therapy and applied relaxation training (ART) are frequently applied, depending on the symptoms of the patients. Meditation is also promoted as a treatment for relieving anxiety symptoms.
The increasing integration of digital and artificial intelligence enabled tools into the medical ecosystem has propelled the panic disorder market growth. Smartphone apps to help manage anxiety have emerged in the market. For instance, the Mindable app, developed by professors at Constructor University in Bremen has been approved to manage panic disorder and agoraphobia. Similarly, Apple has launched their ‘Rootd’, facilitating the consumers with panic conditions.
Panic Disorder Market Segmentation
“Panic Disorder Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Agoraphobia
- Social Anxiety Disorder (SAD)
- Obsessive-Compulsive Disorder (OCD)
- Bipolar Disorder
- Post-Traumatic Stress Disorder (PTSD)
- Specific Phobias, Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Others
- Electroconvulsive Therapy ECT
- Cognitive-Behavioral Therapy (CBT)
- Benzodiazepines (BZD)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Monoamine Oxidase Inhibitors (MAOIs)
- Anti-Depressants
- Tricyclic Antidepressants (TCAs)
- Pregabalin
- Buspirone
- Sertraline
- Others
- Oral
- Parenteral
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
The United States hold a significant panic disorder market share and is likely to continue dominating the market in the coming years as well. With prominent companies prevailing in the region, the frequency of drug development and approvals is high. There is rising awareness on mental health related issues with government and private foundations stepping in with campaigns and seminars to impart relevant knowledge on the issues.
In Europe, traditional techniques like aromatherapy and meditation are on the rise. The EU commission has announced a hefty investment of 6 million euros as a part of their mental health strategy. Moreover, workplace mental health initiatives have also been taken on the psychosocial risks of burnout in offices.
The Asia Pacific panic disorder market value is anticipated to grow with reducing stigmatization of mental health issues. With the help non-profit organizations and government campaigns, the masses are getting more aware about the condition. Moreover, the region is also experiencing improvements in the healthcare ecosystem to provide better treatment alternatives to the patients.
Panic Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd.
- Mylan
- AstraZeneca
- Abbott
- Baxter
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Recordati S.p.A.
- Boehringer Ingelheim International GmbH.
- Neurocrine Biosciences, Inc
- Recordati S.p.A.
- Sanofi
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Panic Disorder Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Panic Disorder Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3.2 France Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Panic Disorder Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Panic Disorder Epidemiology Forecast (2018-2034)
- 5.4 Japan Panic Disorder Epidemiology Forecast (2018-2034)
- 6 Panic Disorder Market Overview – 7MM
- 6.1 Panic Disorder Market Historical Value (2018-2024)
- 6.2 Panic Disorder Market Forecast Value (2025-2034)
- 7 Panic Disorder Market Landscape – 7MM
- 7.1 Panic Disorder Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Panic Disorder Product Landscape
- 7.2.1 Analysis by Diseases Type
- 7.2.2 Analysis by Drug Class
- 7.2.3 Analysis by Route of Administration
- 8 Panic Disorder Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Panic Disorder Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Panic Disorder Market Segmentation – 7MM
- 11.1 Panic Disorder Market by Type
- 11.1.1 Market Overview
- 11.1.2 Agoraphobia
- 11.1.3 Social Anxiety Disorder (SAD)
- 11.1.4 Obsessive-Compulsive Disorder (OCD)
- 11.1.5 Bipolar Disorder
- 11.1.6 Post-Traumatic Stress Disorder (PTSD)
- 11.1.7 Specific Phobias, Generalized Anxiety Disorder (GAD)
- 11.1.8 Major Depressive Disorder (MDD)
- 11.1.9 Others
- 11.2 Panic Disorder Market by Therapy
- 11.2.1 Market Overview
- 11.2.2 Electroconvulsive Therapy ECT
- 11.2.3 Cognitive-Behavioral Therapy (CBT)
- 11.3 Panic Disorder Market by Drug Class
- 11.3.1 Market Overview
- 11.3.2 Benzodiazepines (BZD)
- 11.3.3 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- 11.3.4 Monoamine Oxidase Inhibitors (MAOIs)
- 11.3.5 Anti-Depressants
- 11.3.6 Tricyclic Antidepressants (TCAs)
- 11.3.7 Pregabalin
- 11.3.8 Buspirone
- 11.3.9 Sertraline
- 11.3.10 Others
- 11.4 Panic Disorder Market by Route of Administration
- 11.4.1 Market Overview
- 11.4.2 Oral
- 11.4.3 Parenteral
- 11.5 Panic Disorder Market by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan
- 12 United States Panic Disorder Market
- 12.1 Panic Disorder Market Historical Value (2018-2024)
- 12.2 Panic Disorder Market Forecast Value (2025-2034)
- 12.3 Panic Disorder Market by Disease Type
- 12.4 Panic Disorder Market by Treatment Type
- 13 EU-4 and United Kingdom Panic Disorder Market
- 13.1 Panic Disorder Market Historical Value (2018-2024)
- 13.2 Panic Disorder Market Forecast Value (2025-2034)
- 13.3 Germany Panic Disorder Market Overview
- 13.3.1 Panic Disorder Market by Disease Type
- 13.3.2 Panic Disorder Market by Treatment Type
- 13.4 France Panic Disorder Market Overview
- 13.4.1 Panic Disorder Market by Disease Type
- 13.4.2 Panic Disorder Market by Treatment Type
- 13.5 Italy Panic Disorder Market Overview
- 13.5.1 Panic Disorder Market by Disease Type
- 13.5.2 Panic Disorder Market by Treatment Type
- 13.6 Spain Panic Disorder Market Overview
- 13.6.1 Panic Disorder Market by Disease Type
- 13.6.2 Panic Disorder Market by Treatment Type
- 13.7 United Kingdom Panic Disorder Market Overview
- 13.7.1 Panic Disorder Market by Disease Type
- 13.8 Panic Disorder Market by Treatment Type
- 14 Japan Panic Disorder Market
- 14.1 Panic Disorder Market Historical Value (2018-2024)
- 14.2 Panic Disorder Market Forecast Value (2025-2034)
- 14.3 Panic Disorder Market by Disease Type
- 14.4 Panic Disorder Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Teva Pharmaceutical Industries Ltd
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Sun Pharmaceutical Industries Ltd.
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Mylan
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 AstraZeneca
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Abbott
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.5.6 BaxterFinancial Analysis
- 20.5.7 Product Portfolio
- 20.5.8 Demographic Reach and Achievements
- 20.5.9 Mergers and Acquisition
- 20.5.10 Certifications
- 20.6 Baxter
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Bristol-Myers Squibb Company
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Eli Lilly and Company
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 F. Hoffmann-La Roche Ltd
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 GlaxoSmithKline plc
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Recordati S.p.A.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Boehringer Ingelheim International GmbH.
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Neurocrine Biosciences, Inc
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Recordati S.p.A.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Sanofi
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Panic Disorders Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
